Generate Investment Management Ltd Sells 46,161 Shares of Boston Scientific Corporation $BSX

Generate Investment Management Ltd lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 348,920 shares of the medical equipment provider’s stock after selling 46,161 shares during the quarter. Boston Scientific accounts for about 1.5% of Generate Investment Management Ltd’s portfolio, making the stock its 18th biggest position. Generate Investment Management Ltd’s holdings in Boston Scientific were worth $33,270,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Avity Investment Management Inc. raised its holdings in Boston Scientific by 34.0% during the 4th quarter. Avity Investment Management Inc. now owns 217,749 shares of the medical equipment provider’s stock worth $20,762,000 after buying an additional 55,223 shares during the period. Dakota Wealth Management boosted its holdings in shares of Boston Scientific by 0.5% in the fourth quarter. Dakota Wealth Management now owns 123,244 shares of the medical equipment provider’s stock valued at $11,751,000 after buying an additional 642 shares during the period. Trust Point Inc. boosted its holdings in shares of Boston Scientific by 4.0% in the fourth quarter. Trust Point Inc. now owns 8,829 shares of the medical equipment provider’s stock valued at $842,000 after buying an additional 338 shares during the period. CoreCap Advisors LLC increased its position in shares of Boston Scientific by 39.4% during the fourth quarter. CoreCap Advisors LLC now owns 2,646 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 748 shares in the last quarter. Finally, Mather Group LLC. raised its holdings in shares of Boston Scientific by 9.8% during the fourth quarter. Mather Group LLC. now owns 8,503 shares of the medical equipment provider’s stock worth $811,000 after acquiring an additional 757 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several research reports. UBS Group cut their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Morgan Stanley dropped their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Robert W. Baird cut their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $106.00.

Boston Scientific Stock Down 1.4%

Boston Scientific stock opened at $69.21 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 1-year low of $67.56 and a 1-year high of $109.50. The company has a fifty day simple moving average of $77.45 and a 200 day simple moving average of $90.83. The company has a market cap of $102.86 billion, a P/E ratio of 35.68, a price-to-earnings-growth ratio of 1.08 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the firm posted $0.70 EPS. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.